UnitedHealth Sinks 5% on Medicare Advantage Audit Plan as CMS Moves to “Crush” Medical Fraud

Michael Douglass • 4 minute read
Reviewed by: Michael Douglass
Last updated Nov 17, 2026

jittawit21 from jittawit21 via Canva

Key Takeaways

  • UnitedHealth fell 5% after CMS proposed clawing back Medicare Advantage overpayments as far back as payment year 2018, and Humana and CVS Health fell too.
  • CMS estimates the audits would recover about $9 billion per payment year industry-wide, and UnitedHealth hasn’t sized its share.
  • The stock’s discount to its five-year average multiple looks fair for an unsized bill, and its 2027 outlook is the next test.

UnitedHealth Group (UNH) stock is down 5% today. On Monday, the Centers for Medicare & Medicaid Services (CMS) proposed clawing back Medicare Advantage overpayments as far back as payment year 2018.

CMS Administrator Dr. Mehmet Oz framed the rule, called CRUSH, as a way to “crush fraud, waste, and abuse.” Humana (HUM) and CVS Health (CVS) fell too.

A $9 billion-a-year question

CMS would extrapolate the results of its risk adjustment audits back to payment year 2018, so an error found in a sample of charts would apply to a whole contract. CMS estimates this would recover about $9 billion per payment year.

UnitedHealth is the biggest Medicare Advantage insurer, and CMS premiums made up 44% of its 2025 revenue. It hasn’t sized the hit.

TIKR tracks 26 analysts on UnitedHealth. How many say “Buy”?

See the full breakdown of Buy, Hold, and Sell ratings on UnitedHealth, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See UnitedHealth’s Analyst Ratings

A thin cushion for a big bill

Analysts expect UnitedHealth’s normalized EPS to climb from $16.35 in 2025 to $23.33 in 2027 and $27.04 in 2028:

Bar chart from TIKR of UnitedHealth Group's normalized EPS, actual and consensus estimates, $ per share, fiscal 2023-2028.
UnitedHealth Group (UNH): normalized EPS, actual and consensus estimates, $ per share, fiscal 2023-2028 (TIKR)

Those estimates predate Monday’s proposal, and they need the operating margin to recover after it fell to 4.8% in 2025 from 8.1% in 2024. Any repayment, or a reserve for one, would come out of that thinner margin.

Humana, down 4%, has even more riding on a rebound. It guides to at least $9.50 of adjusted EPS for 2026, and analysts expect $18.45 for 2027. At 27x forward earnings, there’s little room for a clawback.

CVS Health fell less, down 3%. Aetna brought in about a third of its third-quarter revenue, and the stock trades at 11x forward earnings. But Aetna’s lower medical benefit ratio came mainly from its Government business. Can that last if audits reach back to 2018?

A modest discount for an unsized bill

UnitedHealth traded at 18x forward earnings at Monday’s close, below its five-year average of 19x:

Line chart from TIKR of UnitedHealth Group's forward (NTM) P/E, last 5 years.
UnitedHealth Group (UNH): forward (NTM) P/E, last 5 years (TIKR)

Today’s drop takes it to about 17x. That’s a fair discount for a bill nobody can size yet, and nowhere near enough for a big one. Management has promised its 2027 outlook before year-end, and a guide at or above the $23.33 consensus, with some word on audit exposure, would go a long way. Comments on the rule close Jan. 19, 2027, so it could still change.

So what is UnitedHealth stock actually worth?

TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what UnitedHealth could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.

Value UnitedHealth for free

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!

Join thousands of investors worldwide who use TIKR to supercharge their investment analysis.

Sign Up for FREENo credit card required